Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults \>=18 to \<=55 years of age~* Confirmed diagnosis of T1DM, diagnosed prior to age 40 years, and for at least 6 months prior to Screening~* Willing to refrain from using carbohydrate counting to adjust insulin during the study~* Willing and able to wear and operate a continuous glucose monitor~* Willing and able to self-assess blood glucose~* Willing and able to provide written informed consent.~Exclusion Criteria:~* History of type 2 diabetes mellitus or diabetes resulting from acromegaly, Cushing's disease, chronic pancreatitis, or pancreatectomy~* Two or more severe episodes of hypoglycemia that required emergency treatment within 3 months prior to Screening~* Use of premixed insulin~* History of diabetic ketoacidosis within 1 year of screening~* Presence of active hepatic disease or clinically significant abnormal liver function tests~* History of chronic pancreatitis~* Participants with a history of heart attack, severe/unstable angina, or coronary revascularization procedure~* History of clinically significant cardiac arrhythmias within 1 year prior to screening~* Participants with congestive heart failure~* Participants with uncontrolled Stage III hypertension~* History of human immunodeficiency virus (HIV) or hepatitis C~* History of illicit drug or alcohol abuse within 12 months prior to Screening~* Use of any investigational agent or device within 30 days prior to Screening or any therapeutic protein or antibody within 90 days prior to Screening~* Use of medication or herbal supplements taken for weight loss within 2 weeks of screening~* Chronic use of any antidiabetic therapy other than insulin within 2 months prior to Screening~* Use of systemic or inhaled corticosteroids within 2 weeks prior to Screening~* Participants who underwent major surgery within 6 months prior to Screening~* Inability or difficulty swallowing whole tablets or capsules~* Women who were pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Sotagliflozin 400 mg - Pioneer Group (Type: EXPERIMENTAL): Sotagliflozin 400 milligram (mg) (two 200 mg tablets), once daily, orally, before breakfast for 29 days; open label administration.
- Placebo - Expansion Group (Type: PLACEBO_COMPARATOR): Two placebo-matching sotagliflozin tablets, once daily, orally, before breakfast for 29 days; double-blind administration.
- Sotagliflozin 400 mg - Expansion Group (Type: EXPERIMENTAL): Sotagliflozin 400 mg (two 200 mg tablets), once daily, orally, before breakfast for 29 days; double-blind administration.

Based on this trial design, predict the completion outcome and termination type (if applicable).